Trending Stock News

Fine Capital Partners LP Lowered Tronox LTD (TROX) Position by $33.18 Million; Bvf Has Decreased Concert Pharmaceuticals (CNCE) Holding by $29.14 Million; Stock Declined

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Logo

Debra Fine decreased its stake in Tronox Ltd (TROX) by 52.02% based on its latest 2017Q4 regulatory filing with the SEC. Fine Capital Partners Lp sold 1.66 million shares as the company’s stock declined 9.62% with the market. The hedge fund run by Debra Fine held 1.53 million shares of the major chemicals company at the end of 2017Q4, valued at $31.38M, down from 3.19M at the end of the previous reported quarter. Fine Capital Partners Lp who had been investing in Tronox Ltd for a number of months, seems to be less bullish one the $2.12 billion market cap company. The stock decreased 2.59% or $0.46 during the last trading session, reaching $17.33. About 1.29 million shares traded or 26.88% up from the average. Tronox Limited (NYSE:TROX) has risen 9.88% since May 9, 2017 and is uptrending. It has underperformed by 1.67% the S&P500.

Bvf Inc decreased its stake in Concert Pharmaceuticals Inc (CNCE) by 37.17% based on its latest 2017Q4 regulatory filing with the SEC. Bvf Inc sold 1.17 million shares as the company’s stock declined 14.38% with the market. The hedge fund held 1.97 million shares of the health care company at the end of 2017Q4, valued at $50.96M, down from 3.14 million at the end of the previous reported quarter. Bvf Inc who had been investing in Concert Pharmaceuticals Inc for a number of months, seems to be less bullish one the $452.48M market cap company. The stock decreased 1.33% or $0.26 during the last trading session, reaching $19.34. About 142,823 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 26.05% since May 9, 2017 and is uptrending. It has outperformed by 14.50% the S&P500.

Fine Capital Partners Lp, which manages about $1.72 billion and $793.60 million US Long portfolio, upped its stake in Sears Hldgs Corp (NASDAQ:SHLD) by 193,822 shares to 2.88 million shares, valued at $10.30M in 2017Q4, according to the filing.

Among 10 analysts covering Tronox (NYSE:TROX), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. Tronox had 23 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, March 27. The stock of Tronox Limited (NYSE:TROX) earned “Buy” rating by Alembic on Tuesday, August 8. Alembic maintained it with “Buy” rating and $2300 target in Monday, July 31 report. The stock of Tronox Limited (NYSE:TROX) earned “Sell” rating by UBS on Friday, March 2. JP Morgan maintained Tronox Limited (NYSE:TROX) rating on Thursday, January 25. JP Morgan has “Overweight” rating and $22 target. The company was maintained on Monday, March 12 by Barclays Capital. The stock has “Buy” rating by J.P. Morgan on Tuesday, October 24. The company was maintained on Thursday, August 13 by RBC Capital Markets. The firm has “Buy” rating given on Monday, June 5 by Alembic. The rating was downgraded by UBS to “Sell” on Wednesday, April 6.

Investors sentiment increased to 2.06 in 2017 Q4. Its up 0.92, from 1.14 in 2017Q3. It increased, as 19 investors sold TROX shares while 35 reduced holdings. 47 funds opened positions while 64 raised stakes. 81.33 million shares or 29.62% more from 62.74 million shares in 2017Q3 were reported. Invesco reported 0% in Tronox Limited (NYSE:TROX). 10,366 were accumulated by Quantum Cap Mgmt. Gp One Trading Ltd Partnership, a Illinois-based fund reported 198,015 shares. 2.03M are held by Millennium Mgmt Limited Com. Nomura holds 145,000 shares. Clarivest Asset Mgmt Limited holds 0% in Tronox Limited (NYSE:TROX) or 18 shares. Bluecrest Cap Management Limited has invested 0.12% in Tronox Limited (NYSE:TROX). Hanseatic Svcs has 76 shares for 0% of their portfolio. Amer Interest Gp holds 0% or 60,572 shares. Cubist Systematic Strategies Ltd has 41,782 shares for 0.05% of their portfolio. Deutsche Bancshares Ag stated it has 634,121 shares. Tiaa Cref Mgmt Lc has invested 0.11% in Tronox Limited (NYSE:TROX). C M Bidwell & Ltd stated it has 2,270 shares or 0.04% of all its holdings. Assetmark Inc, California-based fund reported 55 shares. Parallax Volatility Advisers Lp reported 113,175 shares.

Investors sentiment increased to 2.62 in Q4 2017. Its up 1.44, from 1.18 in 2017Q3. It improved, as 10 investors sold CNCE shares while 19 reduced holdings. 42 funds opened positions while 34 raised stakes. 15.49 million shares or 6.32% more from 14.57 million shares in 2017Q3 were reported. Parametric Portfolio Assoc Lc stated it has 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Cubist Systematic Strategies Lc holds 0.03% or 18,324 shares in its portfolio. 40 are owned by Howe Rusling. Alps invested in 25,139 shares. State Of Wisconsin Inv Board reported 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Texas-based Dimensional Fund Advisors LP has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Moreover, Arrowstreet Cap Partnership has 0.01% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). 13,800 are owned by Alliancebernstein L P. 1.79 million were reported by Blackrock. Federated Invsts Pa reported 21,923 shares. Susquehanna Intl Gp Limited Liability Partnership holds 0% or 52,232 shares. Numeric Lc has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). United Kingdom-based Gsa Prns Llp has invested 0.11% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Geode Capital Ltd invested in 0% or 167,584 shares. Rhumbline Advisers reported 17,248 shares.

Since January 16, 2018, it had 0 buys, and 6 selling transactions for $2.60 million activity. Cassella James V also sold $213,510 worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Tuesday, April 17.

Bvf Inc, which manages about $999.89M and $829.55 million US Long portfolio, upped its stake in Cytokinetics Inc (NASDAQ:CYTK) by 4.48 million shares to 5.72 million shares, valued at $46.63M in 2017Q4, according to the filing. It also increased its holding in Spring Bk Pharmaceuticals Inc by 170,798 shares in the quarter, for a total of 823,474 shares, and has risen its stake in Forward Pharma A/S.

More recent Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) news were published by: Seekingalpha.com which released: “Concert Pharma completes enrollment in mid-stage study of CTP-543 in autoimmune-related hair loss” on April 25, 2018. Also Nasdaq.com published the news titled: “Research Report Identifies Signature Bank, Concert Pharmaceuticals, Easterly Government Properties, Hilltop …” on April 23, 2018. Seekingalpha.com‘s news article titled: “Vertex Hits Stumbling Block For One Triple-Combo Therapy For Cystic Fibrosis” with publication date: April 30, 2018 was also an interesting one.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *